• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Merit Medical Systems Inc.

    4/1/25 4:23:01 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care
    Get the next $MMSI alert in real time by email
    DEFA14A 1 mmsi-20250401xdefa14a.htm DEFA14A

    ​

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.           )

    Filed by the Registrant [x]

    Filed by a Party other than the Registrant [ ]

    Check the appropriate box:

    [ ]

    Preliminary Proxy Statement

    [ ]

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    [ ]

    Definitive Proxy Statement

    [x]

    Definitive Additional Materials

    [ ]

    Soliciting Material under §240.14a-12

    ​

    Merit Medical Systems, Inc.

    (Name of Registrant as Specified In Its Charter)

    ​

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    [x]

    No fee required.

    [ ]

    Fee paid previously with preliminary materials

    [ ]

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

    ​


    GRAPHIC

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V63292-P26227 MERIT MEDICAL SYSTEMS, INC. 1600 W. MERIT PARKWAY SOUTH JORDAN, UT 84095 MERIT MEDICAL SYSTEMS, INC. 2025 Annual Meeting Vote by May 13, 2025 11:59 PM ET. For shares held in the Merit Medical Systems, Inc. 401(k) Profit Sharing Plan, vote by May 9, 2025 11:59 PM ET. You invested in MERIT MEDICAL SYSTEMS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 14, 2025. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 30, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Virtually at the Meeting* May 14, 2025 2:00 PM MDT Virtually at: www.virtualshareholdermeeting.com/MMSI2025

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V63293-P26227 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. The election of four (4) directors to the Merit Medical Systems, Inc. Board of Directors for a three (3) year term or until their successors are elected and qualified. Nominees: 1a. Thomas J. Gunderson For 1b. Laura S. Kaiser For 1c. Michael R. McDonnell For 1d. F. Ann Millner, Ed.D. For 2. Approval of a non-binding, advisory resolution approving the compensation of the Company’s named executive officers as described in the Merit Medical Systems, Inc. Proxy Statement. For 3. Ratification of the Audit Committee’s appointment of Deloitte & Touche LLP to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025. For NOTE: In their discretion, proxies are authorized to vote upon such other business as may properly come before the meeting or any postponement or adjournment of the meeting.

    Get the next $MMSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MMSI

    DatePrice TargetRatingAnalyst
    3/28/2025$120.00Overweight
    Analyst
    12/11/2024$103.00 → $120.00Equal Weight → Overweight
    Wells Fargo
    6/28/2024$96.00Outperform
    Robert W. Baird
    4/11/2024$88.00Buy
    CL King
    2/7/2024$87.00Neutral
    BofA Securities
    12/21/2023$100.00Hold → Buy
    Canaccord Genuity
    12/20/2022$73.00 → $72.00Buy → Hold
    Canaccord Genuity
    2/25/2022$73.00 → $72.00Outperform
    Raymond James
    More analyst ratings

    $MMSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Lampropoulos Fred P. sold $880,377 worth of shares (10,000 units at $88.04), decreasing direct ownership by 0.97% to 1,019,955 units (SEC Form 4)

    4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

    11/26/25 3:22:04 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Executive Chairman Lampropoulos Fred P. sold $2,182,750 worth of shares (25,000 units at $87.31), decreasing direct ownership by 2% to 1,029,955 units (SEC Form 4)

    4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

    11/24/25 6:00:32 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Executive Chairman Lampropoulos Fred P. sold $1,702,650 worth of shares (20,000 units at $85.13), decreasing direct ownership by 2% to 1,054,955 units (SEC Form 4)

    4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

    11/21/25 10:47:59 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Merit Medical with a new price target

    Analyst initiated coverage of Merit Medical with a rating of Overweight and set a new price target of $120.00

    3/28/25 8:20:21 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Merit Medical from Equal Weight to Overweight and set a new price target of $120.00 from $103.00 previously

    12/11/24 7:56:29 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Robert W. Baird initiated coverage on Merit Medical with a new price target

    Robert W. Baird initiated coverage of Merit Medical with a rating of Outperform and set a new price target of $96.00

    6/28/24 8:04:44 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis

    SOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services ("CMS") has notified Merit that its application for Transitional Pass-Through ("TPT") incremental payment for WRAPSODY® Cell-Impermeable Endoprosthesis ("CIE") procedures in the outpatient and ambulatory surgery center ("ASC") settings requires further consideration prior to CMS making a final decision. CMS notified Merit that it has deferred Merit's application for the WRAPSODY® CIE to the Calendar Year 2027 Outpatient Prospective Payment System rule, making January 1, 2027, the ear

    11/13/25 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial

    The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty (PTA) through 24 monthsThe clinical improvements associated with the WRAPSODY CIE are projected to improve the interventional landscape for hemodialysis patients who experience venous outflow obstructions SOUTH JORDAN, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced positive findings from the randomized AVF arm of the WAVE trial. These findings were presented during the Late-Breaking Clinical Trials sess

    11/5/25 9:00:00 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial

    At 24 months, the target lesion primary patency (TLPP)1 was 41.7%At 24 months, the access circuit primary patency (ACPP)2 was 25.7% SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the Late-Breaking Clinical Trials session at the annual VIVA Foundation3 Venous Endovascular Interventional Strategies (VEINS) conference held in Las Vegas, NV. For the millions of patients diagnosed with advanced kidney disease, hemodialysis is a life-saving treatment that repla

    11/3/25 9:25:00 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    SEC Filings

    View All

    Merit Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

    11/13/25 5:14:59 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

    11/3/25 5:24:14 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Merit Medical Systems Inc.

    10-Q - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

    10/30/25 4:12:21 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MMSI
    Leadership Updates

    Live Leadership Updates

    View All

    Merit Medical Announces Resignation of President, Joseph Wright

    SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance. Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President. ABOUT MERI

    12/16/24 4:00:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Shareholders Elect Silvia M. Perez as New Director

    SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven

    5/16/24 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Executive Leadership Team Update

    Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit

    5/15/24 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Financials

    Live finance-specific insights

    View All

    Merit Medical Reports Third Quarter 2025 Results and Updates Full-Year Guidance

    Highlights† Reported revenue of $384.2 million, up 13.0%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 7.8%, respectivelyGAAP operating margin of 11.1%, compared to 11.0% in prior year periodNon-GAAP operating margin* of 19.7%, compared to 19.2% in prior year periodGAAP EPS $0.46, down 3.0%Non-GAAP EPS* $0.92, up 6.7%Free cash flow* generation of $141.6 million over first nine months of 2025, up 17.6% year-over-year † Comparisons above are calculated for the current quarter compared with the third quarter of 2024, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts. * Const

    10/30/25 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Systems to Announce Third Quarter 2025 Results on October 30, 2025

    SOUTH JORDAN, Utah, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2025, after the close of the stock market on Thursday, October 30, 2025. Merit plans to hold its investor conference call on the same day (Thursday, October 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed

    10/3/25 9:25:00 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Reports Second Quarter 2025 Results and Updates Full-Year Guidance

    Highlights† Reported revenue of $382.5 million, up 13.2%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 6.7%, respectivelyGAAP operating margin of 12.3%, compared to 13.6% in prior year periodNon-GAAP operating margin* of 21.2%, compared to 20.1% in prior year periodGAAP EPS $0.54, down 11.6%Non-GAAP EPS* $1.01, up 9.8%Free cash flow* generation of $89.1 million over first six months of 2025, up 8.1% year-over-yearAcquired Biolife Delaware, L.L.C. ("Biolife"), a manufacturer of hemostatic devices branded as StatSeal® and WoundSeal®Martha Aronson named as new President and Chief Executive Officer, effective October 3, 2025 † Comparisons above are calculate

    7/30/25 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Merit Medical Systems Inc.

    SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

    11/14/24 11:05:03 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

    SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

    2/13/24 5:09:38 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

    SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

    2/12/24 5:32:43 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care